TWI313599B - Novel treatment for obsessive-compulsive disorder (ocd) and ocd-related disorders using gvg - Google Patents
Novel treatment for obsessive-compulsive disorder (ocd) and ocd-related disorders using gvg Download PDFInfo
- Publication number
- TWI313599B TWI313599B TW091109922A TW91109922A TWI313599B TW I313599 B TWI313599 B TW I313599B TW 091109922 A TW091109922 A TW 091109922A TW 91109922 A TW91109922 A TW 91109922A TW I313599 B TWI313599 B TW I313599B
- Authority
- TW
- Taiwan
- Prior art keywords
- ocd
- day
- gvg
- gaba
- acid
- Prior art date
Links
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 title claims description 34
- 238000011282 treatment Methods 0.000 title claims description 9
- 208000021384 Obsessive-Compulsive disease Diseases 0.000 title claims description 5
- 208000035475 disorder Diseases 0.000 claims description 26
- 230000006399 behavior Effects 0.000 claims description 22
- 241000124008 Mammalia Species 0.000 claims description 21
- 239000000203 mixture Substances 0.000 claims description 16
- 150000003839 salts Chemical class 0.000 claims description 16
- 208000011688 Generalised anxiety disease Diseases 0.000 claims description 8
- 208000029364 generalized anxiety disease Diseases 0.000 claims description 8
- 208000001836 Firesetting Behavior Diseases 0.000 claims description 7
- 239000002253 acid Substances 0.000 claims description 6
- 201000010099 disease Diseases 0.000 claims description 6
- 239000003814 drug Substances 0.000 claims description 6
- 206010034158 Pathological gambling Diseases 0.000 claims description 4
- 230000002969 morbid Effects 0.000 claims description 4
- 239000008194 pharmaceutical composition Substances 0.000 claims description 4
- 229920002554 vinyl polymer Polymers 0.000 claims description 4
- 238000004519 manufacturing process Methods 0.000 claims description 3
- 208000028017 Psychotic disease Diseases 0.000 claims description 2
- 230000001575 pathological effect Effects 0.000 claims description 2
- 208000012661 Dyskinesia Diseases 0.000 claims 1
- 230000002079 cooperative effect Effects 0.000 claims 1
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims 1
- 125000000391 vinyl group Chemical group [H]C([*])=C([H])[H] 0.000 claims 1
- 208000030459 obsessive-compulsive personality disease Diseases 0.000 description 50
- 208000007656 osteochondritis dissecans Diseases 0.000 description 50
- PJDFLNIOAUIZSL-UHFFFAOYSA-N vigabatrin Chemical compound C=CC(N)CCC(O)=O PJDFLNIOAUIZSL-UHFFFAOYSA-N 0.000 description 29
- 229960003692 gamma aminobutyric acid Drugs 0.000 description 27
- BTCSSZJGUNDROE-UHFFFAOYSA-N gamma-aminobutyric acid Chemical compound NCCCC(O)=O BTCSSZJGUNDROE-UHFFFAOYSA-N 0.000 description 24
- 238000000034 method Methods 0.000 description 15
- VYFYYTLLBUKUHU-UHFFFAOYSA-N dopamine Chemical compound NCCC1=CC=C(O)C(O)=C1 VYFYYTLLBUKUHU-UHFFFAOYSA-N 0.000 description 10
- 210000004556 brain Anatomy 0.000 description 9
- 239000000126 substance Substances 0.000 description 9
- UGJMXCAKCUNAIE-UHFFFAOYSA-N Gabapentin Chemical compound OC(=O)CC1(CN)CCCCC1 UGJMXCAKCUNAIE-UHFFFAOYSA-N 0.000 description 8
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 7
- NIJJYAXOARWZEE-UHFFFAOYSA-N Valproic acid Chemical compound CCCC(C(O)=O)CCC NIJJYAXOARWZEE-UHFFFAOYSA-N 0.000 description 7
- QZAYGJVTTNCVMB-UHFFFAOYSA-N serotonin Chemical compound C1=C(O)C=C2C(CCN)=CNC2=C1 QZAYGJVTTNCVMB-UHFFFAOYSA-N 0.000 description 6
- 229960003638 dopamine Drugs 0.000 description 5
- 229940079593 drug Drugs 0.000 description 5
- -1 vinyl GABA Chemical compound 0.000 description 5
- 230000008901 benefit Effects 0.000 description 4
- 230000000694 effects Effects 0.000 description 4
- 229960002870 gabapentin Drugs 0.000 description 4
- 208000024891 symptom Diseases 0.000 description 4
- SJZRECIVHVDYJC-UHFFFAOYSA-N 4-hydroxybutyric acid Chemical compound OCCCC(O)=O SJZRECIVHVDYJC-UHFFFAOYSA-N 0.000 description 3
- 241000283690 Bos taurus Species 0.000 description 3
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 3
- 210000003169 central nervous system Anatomy 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 150000001875 compounds Chemical class 0.000 description 3
- 239000003112 inhibitor Substances 0.000 description 3
- 230000002427 irreversible effect Effects 0.000 description 3
- 230000008569 process Effects 0.000 description 3
- 229940002612 prodrug Drugs 0.000 description 3
- 239000000651 prodrug Substances 0.000 description 3
- 229940076279 serotonin Drugs 0.000 description 3
- 229960000604 valproic acid Drugs 0.000 description 3
- RTHCYVBBDHJXIQ-MRXNPFEDSA-N (R)-fluoxetine Chemical compound O([C@H](CCNC)C=1C=CC=CC=1)C1=CC=C(C(F)(F)F)C=C1 RTHCYVBBDHJXIQ-MRXNPFEDSA-N 0.000 description 2
- 208000019901 Anxiety disease Diseases 0.000 description 2
- RGHNJXZEOKUKBD-SQOUGZDYSA-N D-gluconic acid Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C(O)=O RGHNJXZEOKUKBD-SQOUGZDYSA-N 0.000 description 2
- 208000001613 Gambling Diseases 0.000 description 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 2
- 206010028813 Nausea Diseases 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
- 206010036790 Productive cough Diseases 0.000 description 2
- 208000013738 Sleep Initiation and Maintenance disease Diseases 0.000 description 2
- 235000011054 acetic acid Nutrition 0.000 description 2
- 230000009471 action Effects 0.000 description 2
- 230000036506 anxiety Effects 0.000 description 2
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 2
- 235000021028 berry Nutrition 0.000 description 2
- 210000004027 cell Anatomy 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 231100000867 compulsive behavior Toxicity 0.000 description 2
- 229960002464 fluoxetine Drugs 0.000 description 2
- 235000013305 food Nutrition 0.000 description 2
- 238000001727 in vivo Methods 0.000 description 2
- 230000005764 inhibitory process Effects 0.000 description 2
- 206010022437 insomnia Diseases 0.000 description 2
- 230000008693 nausea Effects 0.000 description 2
- 210000002569 neuron Anatomy 0.000 description 2
- 230000036961 partial effect Effects 0.000 description 2
- 230000000737 periodic effect Effects 0.000 description 2
- 208000024794 sputum Diseases 0.000 description 2
- 210000003802 sputum Anatomy 0.000 description 2
- 229960001918 tiagabine Drugs 0.000 description 2
- PBJUNZJWGZTSKL-MRXNPFEDSA-N tiagabine Chemical compound C1=CSC(C(=CCCN2C[C@@H](CCC2)C(O)=O)C2=C(C=CS2)C)=C1C PBJUNZJWGZTSKL-MRXNPFEDSA-N 0.000 description 2
- JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 description 2
- AHOUBRCZNHFOSL-YOEHRIQHSA-N (+)-Casbol Chemical compound C1=CC(F)=CC=C1[C@H]1[C@H](COC=2C=C3OCOC3=CC=2)CNCC1 AHOUBRCZNHFOSL-YOEHRIQHSA-N 0.000 description 1
- WSEQXVZVJXJVFP-HXUWFJFHSA-N (R)-citalopram Chemical compound C1([C@@]2(C3=CC=C(C=C3CO2)C#N)CCCN(C)C)=CC=C(F)C=C1 WSEQXVZVJXJVFP-HXUWFJFHSA-N 0.000 description 1
- BJEPYKJPYRNKOW-REOHCLBHSA-N (S)-malic acid Chemical compound OC(=O)[C@@H](O)CC(O)=O BJEPYKJPYRNKOW-REOHCLBHSA-N 0.000 description 1
- SMZOUWXMTYCWNB-UHFFFAOYSA-N 2-(2-methoxy-5-methylphenyl)ethanamine Chemical compound COC1=CC=C(C)C=C1CCN SMZOUWXMTYCWNB-UHFFFAOYSA-N 0.000 description 1
- NIXOWILDQLNWCW-UHFFFAOYSA-N 2-Propenoic acid Natural products OC(=O)C=C NIXOWILDQLNWCW-UHFFFAOYSA-N 0.000 description 1
- BMYNFMYTOJXKLE-UHFFFAOYSA-N 3-azaniumyl-2-hydroxypropanoate Chemical compound NCC(O)C(O)=O BMYNFMYTOJXKLE-UHFFFAOYSA-N 0.000 description 1
- 241000238876 Acari Species 0.000 description 1
- 239000005711 Benzoic acid Substances 0.000 description 1
- 241001674044 Blattodea Species 0.000 description 1
- 241000282472 Canis lupus familiaris Species 0.000 description 1
- 206010067947 Compulsive sexual behaviour Diseases 0.000 description 1
- RGHNJXZEOKUKBD-UHFFFAOYSA-N D-gluconic acid Natural products OCC(O)C(O)C(O)C(O)C(O)=O RGHNJXZEOKUKBD-UHFFFAOYSA-N 0.000 description 1
- 206010012335 Dependence Diseases 0.000 description 1
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 1
- 206010012735 Diarrhoea Diseases 0.000 description 1
- 241000283086 Equidae Species 0.000 description 1
- 208000010235 Food Addiction Diseases 0.000 description 1
- 102000005915 GABA Receptors Human genes 0.000 description 1
- 108010005551 GABA Receptors Proteins 0.000 description 1
- 208000008454 Hyperhidrosis Diseases 0.000 description 1
- 206010021567 Impulsive behaviour Diseases 0.000 description 1
- RGHNJXZEOKUKBD-QTBDOELSSA-N L-gulonic acid Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)C(O)=O RGHNJXZEOKUKBD-QTBDOELSSA-N 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- 206010029216 Nervousness Diseases 0.000 description 1
- GRYLNZFGIOXLOG-UHFFFAOYSA-N Nitric acid Chemical compound O[N+]([O-])=O GRYLNZFGIOXLOG-UHFFFAOYSA-N 0.000 description 1
- 239000008896 Opium Substances 0.000 description 1
- 241000282520 Papio Species 0.000 description 1
- AHOUBRCZNHFOSL-UHFFFAOYSA-N Paroxetine hydrochloride Natural products C1=CC(F)=CC=C1C1C(COC=2C=C3OCOC3=CC=2)CNCC1 AHOUBRCZNHFOSL-UHFFFAOYSA-N 0.000 description 1
- 241001494479 Pecora Species 0.000 description 1
- 241000288906 Primates Species 0.000 description 1
- 241000283984 Rodentia Species 0.000 description 1
- 206010040007 Sense of oppression Diseases 0.000 description 1
- 201000001880 Sexual dysfunction Diseases 0.000 description 1
- KDYFGRWQOYBRFD-UHFFFAOYSA-N Succinic acid Natural products OC(=O)CCC(O)=O KDYFGRWQOYBRFD-UHFFFAOYSA-N 0.000 description 1
- FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 description 1
- KJADKKWYZYXHBB-XBWDGYHZSA-N Topiramic acid Chemical compound C1O[C@@]2(COS(N)(=O)=O)OC(C)(C)O[C@H]2[C@@H]2OC(C)(C)O[C@@H]21 KJADKKWYZYXHBB-XBWDGYHZSA-N 0.000 description 1
- 206010044565 Tremor Diseases 0.000 description 1
- 208000003443 Unconsciousness Diseases 0.000 description 1
- 208000021017 Weight Gain Diseases 0.000 description 1
- 206010000059 abdominal discomfort Diseases 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 230000005856 abnormality Effects 0.000 description 1
- 229960004047 acamprosate Drugs 0.000 description 1
- AFCGFAGUEYAMAO-UHFFFAOYSA-N acamprosate Chemical compound CC(=O)NCCCS(O)(=O)=O AFCGFAGUEYAMAO-UHFFFAOYSA-N 0.000 description 1
- BUVGWDNTAWHSKI-UHFFFAOYSA-L acamprosate calcium Chemical compound [Ca+2].CC(=O)NCCCS([O-])(=O)=O.CC(=O)NCCCS([O-])(=O)=O BUVGWDNTAWHSKI-UHFFFAOYSA-L 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- BJEPYKJPYRNKOW-UHFFFAOYSA-N alpha-hydroxysuccinic acid Natural products OC(=O)C(O)CC(O)=O BJEPYKJPYRNKOW-UHFFFAOYSA-N 0.000 description 1
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 1
- 229940124277 aminobutyric acid Drugs 0.000 description 1
- 210000004227 basal ganglia Anatomy 0.000 description 1
- 230000003542 behavioural effect Effects 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 235000010233 benzoic acid Nutrition 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 230000008499 blood brain barrier function Effects 0.000 description 1
- 210000001218 blood-brain barrier Anatomy 0.000 description 1
- KDYFGRWQOYBRFD-NUQCWPJISA-N butanedioic acid Chemical compound O[14C](=O)CC[14C](O)=O KDYFGRWQOYBRFD-NUQCWPJISA-N 0.000 description 1
- VSGNNIFQASZAOI-UHFFFAOYSA-L calcium acetate Chemical group [Ca+2].CC([O-])=O.CC([O-])=O VSGNNIFQASZAOI-UHFFFAOYSA-L 0.000 description 1
- 239000001639 calcium acetate Substances 0.000 description 1
- 235000011092 calcium acetate Nutrition 0.000 description 1
- 229960005147 calcium acetate Drugs 0.000 description 1
- 229940058898 campral Drugs 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 210000005056 cell body Anatomy 0.000 description 1
- ZGLIFVFRIOKQLE-LVZFUZTISA-N chembl2104573 Chemical compound C=1C(Cl)=CC=C(O)C=1C(=N/CCCC)/C1=CC=CC=C1Cl ZGLIFVFRIOKQLE-LVZFUZTISA-N 0.000 description 1
- 238000001311 chemical methods and process Methods 0.000 description 1
- 235000015218 chewing gum Nutrition 0.000 description 1
- OEYIOHPDSNJKLS-UHFFFAOYSA-N choline Chemical compound C[N+](C)(C)CCO OEYIOHPDSNJKLS-UHFFFAOYSA-N 0.000 description 1
- 229960001231 choline Drugs 0.000 description 1
- 238000004587 chromatography analysis Methods 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 229960001653 citalopram Drugs 0.000 description 1
- 235000015165 citric acid Nutrition 0.000 description 1
- 238000013270 controlled release Methods 0.000 description 1
- 238000002425 crystallisation Methods 0.000 description 1
- 230000008025 crystallization Effects 0.000 description 1
- 229940089052 depakene Drugs 0.000 description 1
- 150000004985 diamines Chemical class 0.000 description 1
- 235000014632 disordered eating Nutrition 0.000 description 1
- 208000002173 dizziness Diseases 0.000 description 1
- 239000003937 drug carrier Substances 0.000 description 1
- 235000005686 eating Nutrition 0.000 description 1
- 230000008030 elimination Effects 0.000 description 1
- 238000003379 elimination reaction Methods 0.000 description 1
- 230000002996 emotional effect Effects 0.000 description 1
- 239000002532 enzyme inhibitor Substances 0.000 description 1
- 229950004395 fengabine Drugs 0.000 description 1
- CJOFXWAVKWHTFT-XSFVSMFZSA-N fluvoxamine Chemical compound COCCCC\C(=N/OCCN)C1=CC=C(C(F)(F)F)C=C1 CJOFXWAVKWHTFT-XSFVSMFZSA-N 0.000 description 1
- 229960004038 fluvoxamine Drugs 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 210000001652 frontal lobe Anatomy 0.000 description 1
- 239000002843 gaba uptake inhibitor Substances 0.000 description 1
- 239000000174 gluconic acid Substances 0.000 description 1
- 235000012208 gluconic acid Nutrition 0.000 description 1
- 230000003370 grooming effect Effects 0.000 description 1
- FQZPXSRKCOWUEI-UHFFFAOYSA-N hexadecyl 4-aminobutanoate Chemical compound CCCCCCCCCCCCCCCCOC(=O)CCCN FQZPXSRKCOWUEI-UHFFFAOYSA-N 0.000 description 1
- 208000013403 hyperactivity Diseases 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 239000007937 lozenge Substances 0.000 description 1
- 239000001630 malic acid Substances 0.000 description 1
- 235000011090 malic acid Nutrition 0.000 description 1
- 238000002483 medication Methods 0.000 description 1
- 210000004379 membrane Anatomy 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 230000004630 mental health Effects 0.000 description 1
- 150000007522 mineralic acids Chemical class 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 230000001722 neurochemical effect Effects 0.000 description 1
- 239000002858 neurotransmitter agent Substances 0.000 description 1
- 229910017604 nitric acid Inorganic materials 0.000 description 1
- 231100000957 no side effect Toxicity 0.000 description 1
- VIKNJXKGJWUCNN-XGXHKTLJSA-N norethisterone Chemical compound O=C1CC[C@@H]2[C@H]3CC[C@](C)([C@](CC4)(O)C#C)[C@@H]4[C@@H]3CCC2=C1 VIKNJXKGJWUCNN-XGXHKTLJSA-N 0.000 description 1
- 229960001027 opium Drugs 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 235000005985 organic acids Nutrition 0.000 description 1
- 230000008520 organization Effects 0.000 description 1
- IPCSVZSSVZVIGE-UHFFFAOYSA-N palmitic acid group Chemical group C(CCCCCCCCCCCCCCC)(=O)O IPCSVZSSVZVIGE-UHFFFAOYSA-N 0.000 description 1
- 229960002296 paroxetine Drugs 0.000 description 1
- 210000004303 peritoneum Anatomy 0.000 description 1
- 230000002085 persistent effect Effects 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 229960002752 progabide Drugs 0.000 description 1
- IBALRBWGSVJPAP-HEHNFIMWSA-N progabide Chemical compound C=1C(F)=CC=C(O)C=1C(=N/CCCC(=O)N)/C1=CC=C(Cl)C=C1 IBALRBWGSVJPAP-HEHNFIMWSA-N 0.000 description 1
- 230000009103 reabsorption Effects 0.000 description 1
- 102000005962 receptors Human genes 0.000 description 1
- 108020003175 receptors Proteins 0.000 description 1
- 230000002829 reductive effect Effects 0.000 description 1
- 230000003989 repetitive behavior Effects 0.000 description 1
- 208000013406 repetitive behavior Diseases 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 230000035807 sensation Effects 0.000 description 1
- 229960002073 sertraline Drugs 0.000 description 1
- VGKDLMBJGBXTGI-SJCJKPOMSA-N sertraline Chemical compound C1([C@@H]2CC[C@@H](C3=CC=CC=C32)NC)=CC=C(Cl)C(Cl)=C1 VGKDLMBJGBXTGI-SJCJKPOMSA-N 0.000 description 1
- 208000017520 skin disease Diseases 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 239000007858 starting material Substances 0.000 description 1
- 230000004083 survival effect Effects 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 230000035900 sweating Effects 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 239000011975 tartaric acid Substances 0.000 description 1
- 235000002906 tartaric acid Nutrition 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 229960004394 topiramate Drugs 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 239000003981 vehicle Substances 0.000 description 1
- 229960005318 vigabatrin Drugs 0.000 description 1
- 230000003442 weekly effect Effects 0.000 description 1
- 230000004584 weight gain Effects 0.000 description 1
- 235000019786 weight gain Nutrition 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Life Sciences & Earth Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Epidemiology (AREA)
- Psychiatry (AREA)
- Hospice & Palliative Care (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US09/853,392 US6462084B1 (en) | 2001-05-14 | 2001-05-14 | Treatment for obsessive-compulsive disorder (OCD) and OCD-related disorders using GVG |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| TWI313599B true TWI313599B (en) | 2009-08-21 |
Family
ID=25315916
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| TW091109922A TWI313599B (en) | 2001-05-14 | 2002-05-13 | Novel treatment for obsessive-compulsive disorder (ocd) and ocd-related disorders using gvg |
Country Status (18)
| Country | Link |
|---|---|
| US (2) | US6462084B1 (enExample) |
| EP (1) | EP1392273A4 (enExample) |
| JP (1) | JP2004533445A (enExample) |
| KR (1) | KR20040028758A (enExample) |
| CN (1) | CN1509168A (enExample) |
| BR (1) | BR0209614A (enExample) |
| CA (1) | CA2446641A1 (enExample) |
| CZ (1) | CZ20033379A3 (enExample) |
| HR (1) | HRP20030894A2 (enExample) |
| HU (1) | HUP0400032A3 (enExample) |
| IL (1) | IL158761A0 (enExample) |
| MX (1) | MXPA03010406A (enExample) |
| NO (1) | NO20035037L (enExample) |
| NZ (1) | NZ529613A (enExample) |
| PL (1) | PL367362A1 (enExample) |
| TW (1) | TWI313599B (enExample) |
| WO (1) | WO2002092071A1 (enExample) |
| YU (1) | YU89103A (enExample) |
Families Citing this family (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2002227052A1 (en) | 2000-11-30 | 2002-06-11 | University Of Florida | Treatments for neurogenetic disorders, impulse control disorders, and wound healing |
| JP2005534678A (ja) * | 2002-06-27 | 2005-11-17 | ワーナー−ランバート カンパニー リミティド ライアビリティー カンパニー | 注意欠陥多動性障害の治療方法 |
| US7393537B2 (en) | 2003-04-25 | 2008-07-01 | Allergan, Inc. | Botulinum toxin for treatment of obsessive compulsive finger biting disorder |
| WO2004096269A2 (en) * | 2003-04-25 | 2004-11-11 | Allergan, Inc. | Botulinum neurotoxin for treating tics and obsessive compulsive behaviors |
| US20110275664A1 (en) * | 2005-09-26 | 2011-11-10 | The Regents Of The University Of Colorado,A Body Corporate | Method for treating drug and behavioral addictions |
| GB0907413D0 (en) | 2009-04-29 | 2009-06-10 | Equateq Ltd | Novel methods |
| CA2790820A1 (en) * | 2010-02-25 | 2011-09-01 | Northwestern University | Use (1s,3s)-3-amino-4-difluoromethylenyl-1-cyclopentanoic acid as a gaba aminotransferse inhibitor |
| US8293790B2 (en) | 2011-10-19 | 2012-10-23 | Dignity Sciences Limited | Pharmaceutical compositions comprising DGLA and benzoyl peroxide and methods of use thereof |
| AU2012345659B2 (en) | 2011-12-02 | 2017-09-28 | Synchroneuron Inc. | Acamprosate formulations, methods of using the same, and combinations comprising the same |
| US8652527B1 (en) | 2013-03-13 | 2014-02-18 | Upsher-Smith Laboratories, Inc | Extended-release topiramate capsules |
| US9101545B2 (en) | 2013-03-15 | 2015-08-11 | Upsher-Smith Laboratories, Inc. | Extended-release topiramate capsules |
| WO2014197744A1 (en) * | 2013-06-05 | 2014-12-11 | Synchroneuron, Inc. | Acamprosate formulations, methods of using the same, and combinations comprising the same |
| CN104306736A (zh) * | 2014-10-31 | 2015-01-28 | 哈尔滨市海江科技开发有限公司 | 一种治疗疑病症的膏药及其制备方法 |
Family Cites Families (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4761429A (en) | 1985-07-22 | 1988-08-02 | Kenneth Blum | Enkephalinase and endorphinase inhibitors as anti-craving compositions |
| US5189064A (en) | 1985-07-22 | 1993-02-23 | Matrix Technologies, Inc. | Treatment of cocaine addiction |
| US4786647A (en) | 1986-06-30 | 1988-11-22 | University Of Florida | Method for eliciting anxiolysis |
| US4980168A (en) | 1989-10-13 | 1990-12-25 | Natrol, Inc. | Dietary supplement for children |
| EP0767174A1 (de) | 1991-11-21 | 1997-04-09 | Ciba-Geigy Ag | Neue Aminoalkanphosphinsäuren und ihre Salze |
| DK0641330T3 (da) * | 1992-05-20 | 2001-12-03 | Univ Northwestern | Gaba- og L-glutaminsyreanaloger til antikrampeanfaldsbehandling |
| US5792796A (en) * | 1994-07-27 | 1998-08-11 | Warner-Lambert Company | Methods for treating anxiety and panic |
| EP0915697B1 (en) | 1996-06-28 | 2002-09-18 | Ortho-McNeil Pharmaceutical, Inc. | Anticonvulsant sulfamate derivatives useful in treating obesity |
| US5776956A (en) | 1996-07-30 | 1998-07-07 | Lectec Corporation | Use of cotinine in treating psychiatric disorders |
| US6117855A (en) * | 1996-10-07 | 2000-09-12 | Merck Sharp & Dohme Ltd. | Use of a NK-1 receptor antagonist and an antidepressant and/or an anti-anxiety agent |
| IL135659A0 (en) | 1997-10-28 | 2001-05-20 | Schering Corp | Method of reducing craving in mammals |
| US6391922B1 (en) * | 1998-01-13 | 2002-05-21 | Synchroneuron, Llc | Treatment of posttraumatic stress disorder, obsessive-compulsive disorder and related neuropsychiatric disorders |
| US6541520B1 (en) * | 1998-08-05 | 2003-04-01 | Brookhaven Science Associates | Treatment of addiction and addiction-related behavior |
| MXPA01004015A (es) * | 1998-10-20 | 2003-03-10 | Johnson & Johnson | Derivados anticonvulsivos utiles para el tratamiento de la dependencia, adiccion y abuso del alcohol. |
| MXPA01007758A (es) | 1999-02-01 | 2003-06-24 | Johnson & Johnson | Uso de derivados de anticonvulsivos para tratar la bulimia nerviosa. |
| NZ513643A (en) | 1999-02-24 | 2005-04-29 | Univ Cincinnati | Use of sulfamate derivatives for treating impulse control disorders |
| AU4050100A (en) | 1999-04-08 | 2000-11-14 | Ortho-Mcneil Pharmaceutical, Inc. | Anticonvulsant derivatives useful in maintaining weight loss |
| AU2002227052A1 (en) * | 2000-11-30 | 2002-06-11 | University Of Florida | Treatments for neurogenetic disorders, impulse control disorders, and wound healing |
-
2001
- 2001-05-14 US US09/853,392 patent/US6462084B1/en not_active Expired - Fee Related
-
2002
- 2002-05-08 HU HU0400032A patent/HUP0400032A3/hu unknown
- 2002-05-08 BR BR0209614-5A patent/BR0209614A/pt not_active IP Right Cessation
- 2002-05-08 JP JP2002588988A patent/JP2004533445A/ja active Pending
- 2002-05-08 PL PL02367362A patent/PL367362A1/xx not_active Application Discontinuation
- 2002-05-08 NZ NZ529613A patent/NZ529613A/en unknown
- 2002-05-08 IL IL15876102A patent/IL158761A0/xx unknown
- 2002-05-08 CA CA002446641A patent/CA2446641A1/en not_active Abandoned
- 2002-05-08 KR KR10-2003-7014792A patent/KR20040028758A/ko not_active Withdrawn
- 2002-05-08 YU YU89103A patent/YU89103A/sh unknown
- 2002-05-08 HR HR20030894A patent/HRP20030894A2/hr not_active Application Discontinuation
- 2002-05-08 CZ CZ20033379A patent/CZ20033379A3/cs unknown
- 2002-05-08 EP EP02729142A patent/EP1392273A4/en not_active Withdrawn
- 2002-05-08 MX MXPA03010406A patent/MXPA03010406A/es active IP Right Grant
- 2002-05-08 CN CNA028098269A patent/CN1509168A/zh active Pending
- 2002-05-08 WO PCT/US2002/014344 patent/WO2002092071A1/en not_active Ceased
- 2002-05-13 TW TW091109922A patent/TWI313599B/zh not_active IP Right Cessation
- 2002-06-20 US US10/175,576 patent/US20020169103A1/en not_active Abandoned
-
2003
- 2003-11-13 NO NO20035037A patent/NO20035037L/no not_active Application Discontinuation
Also Published As
| Publication number | Publication date |
|---|---|
| CA2446641A1 (en) | 2002-11-21 |
| JP2004533445A (ja) | 2004-11-04 |
| NO20035037L (no) | 2004-01-07 |
| HUP0400032A3 (en) | 2012-09-28 |
| PL367362A1 (en) | 2005-02-21 |
| HRP20030894A2 (en) | 2004-06-30 |
| MXPA03010406A (es) | 2004-05-05 |
| WO2002092071A1 (en) | 2002-11-21 |
| BR0209614A (pt) | 2004-12-07 |
| YU89103A (sh) | 2006-08-17 |
| KR20040028758A (ko) | 2004-04-03 |
| NZ529613A (en) | 2006-09-29 |
| CZ20033379A3 (cs) | 2004-12-15 |
| EP1392273A4 (en) | 2004-11-24 |
| US20020169103A1 (en) | 2002-11-14 |
| HUP0400032A2 (hu) | 2004-04-28 |
| CN1509168A (zh) | 2004-06-30 |
| IL158761A0 (en) | 2004-05-12 |
| EP1392273A1 (en) | 2004-03-03 |
| NO20035037D0 (no) | 2003-11-13 |
| US6462084B1 (en) | 2002-10-08 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AU2021382158C1 (en) | Mdma prodrugs to assist psychotherapy | |
| EP3930841A1 (en) | A formulation for improving seizure control | |
| US20090137565A1 (en) | Method for treatment of movement disorders | |
| US20210338691A1 (en) | Methods for treating sleep disorders, sleep disturbances, and related symptoms using aminosterol compositions | |
| JPH02240021A (ja) | 抑うつ障害の治療用に適した制御放出製薬組成物 | |
| US12220389B2 (en) | Combination therapy for the treatment of tinnitus and other medical conditions | |
| US6462084B1 (en) | Treatment for obsessive-compulsive disorder (OCD) and OCD-related disorders using GVG | |
| WO2017024129A1 (en) | Combination therapy using acamprosate and d-cycloserine | |
| Akhtar et al. | Local anesthetic drugs used in dentistry | |
| AU2018371628B2 (en) | Benzoic acid or a salt and derivative thereof for use in preventing or treating depression | |
| RU2127589C1 (ru) | Способ лечения стрессорных поражений нервной системы | |
| AU2002259153B2 (en) | Novel treatment for obsessive-compulsive disorder (OCD) and OCD-related disorders using GVG | |
| Liu¹t et al. | Pharmacological interventions | |
| Heinig et al. | Rapid attainment of steady-state acetylcholinesterase inhibition by administration of metrifonate loading and maintenance doses once-daily in elderly volunteers | |
| JP2008506630A (ja) | ゾルピデムの更なる治療的使用 | |
| AU2002259153A1 (en) | Novel treatment for obsessive-compulsive disorder (OCD) and OCD-related disorders using GVG | |
| Tyagi et al. | EFFECT OF ADJUVANT ANTICHOLINESTERASE THERAPY FOR THE MANAGEMENT OR TREATMENT OF EPILEPSY. | |
| TWI291872B (en) | Compositions including modafinil for treatment of attention deficit hyperactivity disorder and multiple sclerosis fatigue | |
| Shea | From the neurobiologic basis of alcohol dependency to pharmacologic treatment strategies: bridging the knowledge gap | |
| WORCESTER | Arthritis Effects Hit Minorities Disproportionately | |
| Bondarenko et al. | Membrane-protective effect of delta-sleep inducing peptide | |
| Linford Rees | The treatment of anxiety states by drugs and other means | |
| Starr | Rx PAD | |
| Horiguchi et al. | The effect of valproate on delirium and aggressive behavior in the demented patients: A preliminary study | |
| Kosaka et al. | Event-related potentials study of acetylcholinesterase inhibitor in patients with Alzheimer-type dementia |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| MM4A | Annulment or lapse of patent due to non-payment of fees |